ArticleMedicine international
Transient myoclonic state or transient myoclonic state with asterixis: A systematic review.
Article in Medicine international. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transient myoclonic state (TMS) is a rare type of myoclonic jerks occurring predominantly in the upper extremities involving the head and commonly associated with asterixis. The present study performed a systematic review of published articles on this condition. For this purpose, six databases were searched by two reviewers to identify reports on TMS published online until November, 2024. A total of 17 reports containing 78 cases were found. Almost all the reports were from Japan, apart from one case reported in the USA. The mean age of the patients was 75.67 years (standard deviation, 5.8 years) and the median age was 75 years (range, 54 to 84 years). Sex was reported in 74 reports, and 60.8% of the patients were males. A precipitating factor, such as an infectious disease or the introduction of a new medication was observed in 24 cases (30.7%). All individuals achieved full recovery; however, 53 patients (67.9%) required benzodiazepine therapy, while the remaining individuals improved spontaneously. In summary, the present systematic review demonstrates that TMS is a rare condition, and is mainly encountered in Japan by unknown factors. There are likely genetic and environmental factors involved in its development; however, no specific geolocation related to the occurrence of TMS in Japan was found. It has a benign course and usually improves with the prescription of benzodiazepines. Management strategies include ensuring adequate multidisciplinary care coordination, as well as educating patients and their families about TMS. Future studies are required to describe the cases of TMS, including videos of the phenomenology. It is also recommended to perform whole genome sequencing analysis in patients with TMS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.